The FDA granted a fast track designation to ST101 for the treatment of advanced cutaneous melanoma in patients who have disease progression on or after anti-PD-1/anti-PD-L1 therapy.
Regulatory
NICE recommends monotherapy for adjuvant treatment of stage 3 melanoma
The approval follows a successful period of monitoring and patient access through the Cancer Drugs Fund.
FDA Grants Fast Track Status to UVI Plus Checkpoint Inhibition for Melanoma Subgroup
The FDA has granted a fast track designation to UV1, a universal cancer vaccine, in combination with either pembrolizumab (Keytruda) or…
FDA Grants Fast Track Status to Cancer Vaccine UV1 for Advanced Malignant Melanoma
The FDA has granted a fast track designation to the universal cancer vaccine UV1 for use in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma…